Therapeutic advances across cancers and inflammatory diseases still have limited effectiveness (40%-60%). Fibrosis contributes to nearly half of all deaths in the UK, yet effective therapeutics are lacking, and no treatments exist for most rare conditions.
The health impact is heightened by inequality and comorbidity of the North West (NW). With our international leaders in Next Generation Therapeutics (NGT), we will develop methods to pull through discovery and identify NGT to the most promising indication(s) and develop novel trial designs to progress to translation, integrating our expertise together with patients and users into a dedicated and agile platform.
Manchester BRC along with our partners across the NW including the NW Clinical Research Facility Alliance will ensure access of NGT studies to this population with a high burden of deprivation and widening health inequalities, creating the opportunity to embed experimental medicine trials and ‘follow patients’ long term outcomes.
Creating a better-informed population that will improve our studies, enable equality, diversity and inclusion, to ensure the benefits reach the typically under-served sections of society.
Our programmes of work in NGT are:
- A methodological and inclusive platform
- Designing innovative trial designs
- Precision therapeutics of high-risk groups and high burden diseases
- Nanoscale-based technologies and advanced biomaterials to improve health needs
- Advanced Therapy Medicinal Products for resistant cancers and rare conditions